Sunday November 08 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
  • A-Z

 BioJournal - LeadDiscovery (background)
To view descriptions and buy online - click here!
BAFF (BLys) & APRIL: Emerging Targets for autoimmu BAFF (BLys) & APRIL: Emerging Targets for autoimmu
In 1999 Human Genome Sciences researchers published a study in the journal Science describing a new member of the TNF super-family which they named BLyS. Since that time our understanding of this protein, also known as BAFF, and its homologue APRIL has progressed rapidly. The BAFF sub-family has emerged as a candidate target for therapies of various autoimmune diseases and hematological cancers with breathtaking speed.
Autoimmune Disorders & Transplant Rejection - Oppo Autoimmune Disorders & Transplant Rejection - Oppo
Affecting as many as 5% of the population, autoimmune disease represents a major clinical problem. Ranking alongside other major conditions such as type II diabetes, in terms of prevalence this group of diseases includes a large number of different conditions of varying prevalence, associated morbidity and disability, and available clinical options. Despite the fragmentation of this market it has proved lucrative for the drug development sector with the emergence of TNF blockers, therapeutics that have now been approved for multiple indications in this market. Global sales of TNF blockers now exceed $5 billion.
Histone deacetylase inhibitors: Moving from the be Histone deacetylase inhibitors: Moving from the be
The field of histone deacetylase inhibitors is moving into a new phase of development. The exponential growth in the level of research activity surrounding the histone deacetylases (HDACs) witnessed over the past decade has now started to produce success in the clinic, particularly in the field of oncology.
5-HT7 antagonists: Novel molecules for the unmet m 5-HT7 antagonists: Novel molecules for the unmet m
The migraine market was revolutionized by the launch of the prototypic triptan, sumatriptan in the early 1990's. Due to the high incidence of migraine and its effect on quality of life the highly competitive triptan market is now worth in excess of $2 billion in global sales.
The retinoids : Therapeutic & pharmaceutical oppor The retinoids : Therapeutic & pharmaceutical oppor
Members of the retinoid family have long been known to be physiological regulators of a range of essential biological processes, including vision, embryonic development, reproduction, and bone formation. Similarly, their modulation of cell metabolism, growth, differentiation, proliferation and apoptosis has brought the retinoids to the forefront of oncology.
Rheumatoid arthritis: Emerging drug discovery targ Rheumatoid arthritis: Emerging drug discovery targ
The autoimmune diseases are receiving increasing attention in the pharmaceutical industry as progress is made in the understanding of immune and inflammatory processes. It is predicted that the annual value of the market for drugs used to treat autoimmune disease will exceed $20 billion in the next few years. Rheumatoid arthritis is one of the more common and difficult to treat autoimmune diseases and there is a great deal of interest in the discovery of novel drugs to treat this condition.
Asthma Therapeutics: New treatment options and eme Asthma Therapeutics: New treatment options and eme
This report produced by LeadDiscovery in collaboration with head of Thoracic Medicine at the National Heart and Lung Institute, asthma field-leader and panelist for the Global Initiative for Asthma (GINA), Professor Peter Barnes, focuses on the evaluation of emerging asthma therapeutics and provides a state of the art analysis of those drug discovery targets destined to underlie future therapeutics.
Aurora Kinase inhibitors Aurora Kinase inhibitors
Cell cycle inhibitors represent a key approach to the treatment of cancer. Therapeutic agents have traditionally targeted early stages of the cell cycle (ie the G1/S phase checkpoint or the S phase) or mitotic spindle formation as exemplified by the alkaloids. Recently a new approach to cell cycle regulation has emerged with the identification of the Aurora kinase family. This family plays a role in later stages of the cell cycle from the G2/M check point all the way through to the mitotic checkpoint and late mitosis.

 

To view descriptions and buy online - click here!
 

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright © 1997-2009 - BioPortfolio Limited.